Highlights Genmab A/S

Stocks

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-15 EDT			5-day change	1st Jan Change
1,594.00 ^DKK	-1.54%		+0.66%	-21.36%

12:57am	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

Highlights

06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
05-07	Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Genmab Q1 Net Profit Falls, Revenue Rises	MT
05-07	Genmab reports Q1 operating profit of $180 million	RE
05-07	Genmab A/S maintains Financial Guidance for 2026	CI
04-14	Genmab Posts Higher Darzalex Net Sales in Q1	MT
04-14	Genmab Q1 Darzalex net sales at $3,964 mln	RE
04-13	Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian Cancer	CI
03-16	Genmab Wraps Up Share Repurchase Program	MT
03-16	Genmab completed share buy-back program on March 13	RE
03-16	H Lundbeck A S Presents New Phase 1b Data for Lu Af28996 and Advances Pipeline in Movement Disorders	CI
02-19	BofA Bullish on Genmab's FY26 Catalyst Path; Buy Rating Maintained	MT
02-18	Genmab: 2025 miss and cautious 2026 targets erode investor confidence
02-18	Genmab FY oper profit up at $1,065 mln	RE
02-17	Genmab announces initiation of share buy-back program	RE
02-17	Genmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued	MT
02-17	(GMAB) Genmab Expects 2026 Revenue Range $4.07B - $4.40B, vs. FactSet Est of $4.32B	MT
02-17	Genmab A/S Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-17	Genmab Provides Earnings Guidance for the Full Year 2026	CI
02-03	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT
01-21	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
01-20	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
01-16	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
01-07	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI